

Date: 31-10-2019

To  
Mr. BhushanMokashi  
Manager  
Bombay Stock Exchange Limited,  
PhirozeJeeJeebhoy Towers,  
Dalal Street, MUMBAI – 400 001.

Sir,

Sub: Outcome of the Board Meeting – Reg.  
Ref: Our Company code no: 532041.

\*\*\*

The following is the Outcome of the Board Meeting of the Company held on 31<sup>st</sup> October, 2019 at 03.00 P.M. at the registered office of the Company:


- 1 The Board has approved the un-audited financial results of the company for the quarter and half year ended on 30<sup>th</sup> September, 2019.

We are herewith enclosing un-audited financial results of the company & Limited Review Report certified by the auditor for the quarter ended 30.09.2019, as per Clause 33 (3) of SEBI (LODR) Regulations, 2015.

This is for your information and record.

Thanking you

Yours faithfully,  
For Hindustan Bio Sciences Limited

  
\*  
J V R Mohan Raju  
Managing Director



HINDUSTAN BIO SCIENCES LIMITED

Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034

Phone No. 23555161, Fax 40205171

STATEMENT OF UN-AUDITED RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2019

Sl. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2019 (Unaudited)	30.06.2019 (Unaudited)	30.09.2018 (Unaudited)	30.09.2019 (Unaudited)	30.09.2018 (Unaudited)	31.03.2019 (audited)
1	Income from Operations						
	(a) Revenue from operations	13.95	57.52	147.39	71.47	206.26	356.34
	(b) Other Income	0	-	-	-	-	0.06
	Total Revenue ( 1)	13.95	57.52	147.39	71.47	206.26	356.40
2	Expenses						
	(a) cost of material consumed	-	-	-	-	-	-
	(b) Purchases of Stock -in-trade	6.43	49.57	160.09	56.00	195.26	292.13
	( c) Changes in Inventories of finished goods, Stock - In-Trade and Work-in-Progress	9.39	(19.07)	(24.10)	(8.68)	(16.17)	(3.45)
	(d) Employee Benefit Expenses	6.30	6.34	5.07	12.64	9.99	22.41
	(e) Finance Costs	0.30	0.17	0.13	0.47	0.35	1.04
	(f) Selling Expenses	0.15	0.09	0.14	0.24	0.47	1.63
	(g) Depreciation and amortisation Expenses	0.32	0.28	0.27	0.60	0.53	1.07
	h) Other Expenses	5.29	5.24	3.46	11.53	13.68	30.34
	Total Expenses( 2 )	28.18	43.62	145.06	71.80	204.11	345.17
3	Profit/(Loss) before Exceptional& Extraordinary Items and tax (1 -2)	(14.23)	13.90	2.33	(0.33)	2.15	11.23
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	(14.23)	13.90	2.33	(0.33)	2.15	11.23
6	Tax Expenses						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax	-	-	-	-	-	(0.23)
7	Profit /(Loss) for the period from continuing operations(5-6)	(14.23)	13.90	2.33	(0.33)	2.15	11.00
8	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-	-	-
11	Profit/(Loss) for the period(7+10)	(14.23)	13.90	2.33	(0.33)	2.15	11.00
12	Other Comprehensive Income						
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	(14.23)	13.90	2.33	(0.33)	2.15	11.00
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						(808.72)
16	Earnings per equity share for continuing operations						
	(A) Basic	(0.14)	0.14	0.02	(0.00)	0.02	0.11
	(B) Diluted	(0.14)	0.14	0.02	(0.00)	0.02	0.11
17	Earnings per equity share for discontinuing operations						
	(A) Basic	-	-	-	-	-	-
	(B) Diluted	-	-	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations						
	(A) Basic	(0.14)	0.14	0.02	(0.00)	0.02	0.11
	(B) Diluted	(0.14)	0.14	0.02	(0.00)	0.02	0.11



**HINDUSTAN BIO SCIENCES LIMITED**  
 Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034  
 Phone No. 23555161, Fax 40205171  
**STATEMENT OF ASSETS AND LIABILITIES**

Rs. in lakhs

PARTICULARS	As at	
	30.09.2019	31.03.2019
<b>ASSETS</b>		
1 Non Current Assets		
(a) Fixed Assets		
Tangible Assets	6.28	5.91
(b) Deferred Tax Asset	2.77	2.77
(c) Long Term Loans & Advances	353.78	353.89
<b>Total Non Current Assets</b>	<b>362.83</b>	<b>362.57</b>
2 Current Assets		
(a) Stock in Trade	21.06	11.38
(b) Trade Receivables	95.84	167.44
(c) Cash and Cash Equivalents	5.58	18.34
(d) Short Term Loans and Advances	4.49	3.20
<b>Total Current Assets</b>	<b>126.97</b>	<b>200.36</b>
<b>TOTAL ASSETS</b>	<b>489.80</b>	<b>562.93</b>
<b>EQUITY AND LIABILITIES</b>		
1 Share Holders Funds		
(a) Share Capital	1025.08	1025.08
(b) Reserves and Surplus	(809.05)	(808.72)
<b>Total of Share Holders Funds</b>	<b>216.03</b>	<b>216.36</b>
2 Non Current Liabilities		
(a) Long Term Borrowings	147.83	226.43
<b>Total Non Current Liabilities</b>	<b>147.83</b>	<b>226.43</b>
3 Current Liabilities		
(a) Short Term Borrowings	122.67	110.17
(b) Trade Payables		
i. Total Outstanding dues of Micro Enterprises & Small Enterprises	0.15	0.15
ii Total Outstanding dues of Creditors other than Micro Enterprises and small enterprises	0.32	6.17
Other Current Liabilities	0	0
Short Term Provisions	2.80	3.65
<b>Sub Total -Current Liabilities</b>	<b>125.94</b>	<b>120.14</b>
<b>TOTAL EQUITY AND LAIBILITIES</b>	<b>489.80</b>	<b>562.93</b>

**Notes:**

- 1 The Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.10.2019
- 2 Previous Year figures have been regrouped wherever necessary.

Place: Hyderabad  
 Date : 31.10.2019

for Hindustan Bio Sciences Limited

J.V.R.Mohan Raju  
 Managing Director







**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

Review Report to  
**The Board of Directors of**  
**M/s HINDUSTAN BIO SCIECNES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **M/s HINDUSTAN BIO SCIECNES LIMITED** for the half year ended September 30, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **C RAMACHANDRAM & Co.,**  
Chartered Accountants  
FRNo.002864S

Place: Hyderabad  
Date: October 31, 2019



  
**C RAMACHANDRAM**  
Partner

Membership No. 025834  
UDIN: 19025834AAAA WH5659